RxDoctor Payments Data

Thomas Atwater, MD

Pulmonary Disease · Nashville, TNNPI 1205194115

Payments from drug & device makers

$7,056in general payments, 2019–2025

Across 21 payments — averaging $336.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • AstraZeneca$166
  • Avita Medical Americas, LLC$51
  • Insmed, Inc.$49
  • Philips North America LLC$31
  • Sanara Medtech Inc.$25
  • plus $60 from 4 others

What the payments were for

  • Travel & lodging$1,09215%
  • Food & beverage$4156%
  • Education$5,54979%

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,056 in reported general payments places this provider in the 60th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$114,477
Medicare patients
385
Services billed
1,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$140,403
Fasenra PenBenralizumab15$92,696
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$53,528
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr72$48,933
Spiriva RespimatTiotropium Bromide50$46,769
Breo ElliptaFluticasone/Vilanterol36$29,536
SymbicortBudesonide/Formoterol Fumarate42$15,131
Fluticasone-SalmeterolFluticasone Propion/Salmeterol52$12,232
Advair HfaFluticasone Propion/Salmeterol18$10,120
Albuterol Sulfate HfaAlbuterol Sulfate192$7,103
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$3,012
Ventolin HfaAlbuterol Sulfate15$1,189
Montelukast Sodium71$1,162
Azithromycin55$1,076
Fluticasone Propionate20$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$17$218,872233 claims
AstraZenecaBreztri Aerosphere, Symbicort$166$68,65990 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →